Peptide HPLC purity — what ≥98% actually means.

Knowing what HPLC purity actually measures on a peptide Certificate of Analysis is the difference between accepting a spec at face value and understanding what the chemistry can (and can’t) tell you about the molecule in the vial.

HPLC has been the workhorse of peptide analytical chemistry for over 40 years. Reverse-phase HPLC separates peptides by hydrophobicity. You dissolve a sample, inject it onto a column packed with C18-functionalized silica beads, and elute it with a gradient of increasing organic solvent (typically acetonitrile in water with a trifluoroacetic acid modifier).

Hydrophilic peptides come off first. Hydrophobic peptides come off later. The eluting compounds pass through a UV detector that watches absorbance at 214 nm, where peptide bonds absorb strongly. You get a chromatogram with time on the x-axis, absorbance on the y-axis, and peaks for each eluted compound.

The mechanics are simple. The interpretation needs care. Several details — what the wavelength captures, how peak integration works, what the percentage does and doesn’t mean — shape what an HPLC purity spec actually tells you.

Why 214 nm?

UV detection at 214 nm is the standard for peptide purity because the peptide bond (the amide linkage between consecutive amino acids) absorbs strongly there. Every peptide contains peptide bonds. So 214 nm detection picks up essentially all peptide-class compounds in the sample, no matter the amino acid composition. Absorbance is proportional to peptide bond count, which means longer peptides absorb more strongly per molecule than shorter ones at the same concentration.

Some CoAs report purity at additional wavelengths. 220 nm captures the same peptide-bond signal slightly off-peak (sometimes preferred when there’s strong 214 nm interference). 254 nm picks up aromatic side chains (tryptophan, tyrosine, phenylalanine). 280 nm is the classic protein absorbance wavelength — mainly tryptophan and tyrosine. Each wavelength tells you slightly different things. 214 nm stays standard because of its near-universal coverage.

Wavelength choice matters because purity is wavelength-dependent. A sample at ≥98% pure at 214 nm may show slightly different purity at 280 nm if the impurity peaks contain different ratios of aromatic side chains than the main peak. Single-wavelength reporting is the convention, but the chemistry of impurities can produce small wavelength-specific variations.

What does the C18 column actually do?

The C18 column is the stationary phase that creates the separation. Silica beads (typically 3–5 µm diameter) are surface-functionalized with octadecyl (C18) hydrocarbon chains. That creates a hydrophobic surface that interacts more strongly with hydrophobic peptide regions and less with hydrophilic ones. Under the mobile-phase gradient, peptides partition between the C18 surface and the increasingly organic mobile phase. The differential retention is what produces the separation.

For peptide analysis, the typical column is 50–150 mm long with 2.1–4.6 mm internal diameter, packed with sub-5-µm C18 silica.

Method development involves picking the mobile phase (usually water and acetonitrile, both with 0.1% TFA), the gradient (linear from 5–95% organic over 15–60 minutes), the flow rate (0.3–1.5 mL/min), and column temperature (25–40°C). Different conditions produce different chromatographic profiles for the same sample. Method validation under ISO 17025 documents the specific conditions and resolution characteristics.

A well-developed peptide HPLC method achieves baseline resolution between the main peak and impurity peaks. The chromatogram returns to baseline between peaks, which lets you cleanly integrate each independently. Poor resolution produces overlapping peaks that complicate integration. That leads to either over- or under-estimation of main-peak purity, depending on how the integration software handles the overlap.

BPC-157

Pentadecapeptide 15 aa Gastric origin

The same reference compound documented through validated HPLC methods in this guide. Lab-verified identity and purity.

View BPC-157

How is the purity percentage calculated?

You integrate the area under each peak and express the main peak area as a percentage of the total integrated signal. The formula:

Purity (%) = (Area of main peak / Total area of all peaks) × 100

Two details matter. First, the total area includes all peaks above a defined baseline threshold — small peaks below the threshold (the “integration limit”) don’t count. Threshold choice affects the calculated purity, especially for samples with many small impurity peaks. Second, the calculation assumes all peaks respond equally at the detection wavelength, which is only approximately true. Peptides with different amino acid compositions can have different molar absorptivity at 214 nm. The calculated percentage represents the area distribution, not strictly the molar distribution.

For most research-grade work, the area-percentage convention is standard. It’s reasonably accurate when impurities are related compounds (truncated sequences, modified residues) with similar amino acid composition to the main peak. For samples with structurally very different impurities, the area-percentage may diverge slightly from the true molar percentage.

What does 98% vs 99% actually look like?

The difference between purity specs is more than a marketing distinction. Each step corresponds to roughly an order-of-magnitude reduction in impurity content:

• ≥95% pure: up to 5% impurities by chromatographic area. Typical for routine research-grade prep where the application can tolerate a modest impurity fraction.
• ≥98% pure: up to 2% impurities. The conventional minimum for higher-quality research-grade peptides. Most reputable suppliers ship at this spec or better.
• ≥99% pure: up to 1% impurities. A meaningful step up. Typically requires additional purification (preparative HPLC, recrystallization, ion-exchange chromatography) after the initial synthesis.
• >99% pure / ≥99.5% pure: up to 0.5% impurities. Pharmaceutical-grade or reference-standard. Requires multiple orthogonal purification steps and rigorous analytical verification.

Each tier costs more. Synthesis itself produces 70–90% crude purity for short peptides (lower for long ones). Purification steps add cost, reduce yield, and need extra analytical verification. For most research-grade work, ≥98% is the practical sweet spot. For reference-standard quality or specific impurity-profile control, you go higher.

Why purity isn’t identity

This is the conceptual point most often misunderstood. HPLC tells you the sample contains one dominant chromatographic peak that’s ≥98% (or whatever spec) of the integrated signal. It does not tell you what that peak actually is.

The peak could be the labeled peptide at ≥98% purity. It could be a different peptide of similar hydrophobicity that co-elutes at the same retention time. It could be a completely misidentified compound. HPLC alone can’t distinguish these, because retention is driven by hydrophobicity, not by molecular identity.

Identity confirmation needs analytical methods that probe molecular structure directly. The most common is mass spectrometry, typically ESI-MS (electrospray ionization) or MALDI-MS (matrix-assisted laser desorption). It measures molecular mass and compares it to the theoretical mass of the labeled peptide.

Match within a few ppm? Strong evidence of identity. For higher confidence, tandem MS fragments the molecule and checks the fragment pattern against the expected sequence. Even higher confidence: peptide mapping or amino acid analysis to verify residue composition.

The practical takeaway: a purity spec alone isn’t enough. A credible CoA includes both an HPLC purity result and identity confirmation by mass spec, peptide mapping, or amino acid analysis. The combination is what separates verified peptide identity from a chromatographically clean sample of unknown composition.

What are the typical impurities?

The minor peaks in a peptide HPLC chromatogram fall into a small number of structural categories. Knowing what they are helps you read the chromatographic profile:

Truncated sequences. SPPS involves sequential coupling of amino acids. Incomplete coupling at any step produces a truncated peptide missing one or more residues. These elute slightly differently from the full-length peptide and appear as discrete impurity peaks.

Deletion sequences. Similar to truncations but missing internal residues rather than terminal ones. Harder to separate chromatographically from the main peak, depending on which residue is missing and its position.

Modified residues. Side-chain protecting groups that didn’t fully cleave, or oxidized residues (methionine sulfoxide, oxidized cysteine), produce slightly altered variants with similar but not identical retention times.

Diastereomers and epimers. Some coupling and deprotection steps can produce small fractions of D-isomer at residues that should be L-isomer. Identical mass but slightly different conformations. Sometimes separable chromatographically.

Aggregates and adducts. Hydrophobic peptides can form dimeric or oligomeric aggregates that produce additional peaks at later retention times. Counter-ion adducts (TFA, sodium) can do the same.

GHK-Cu

10 mg ≥99% pure Lyophilized

Copper-binding tripeptide · Gly-His-Lys, blue lyophilized powder. The same reference compound documented through validated HPLC and mass-spectrometric workflows. COA available with each lot.

Learn more

Mass spectrometry: the identity check

Mass spectrometry complements HPLC purity by giving you the identity confirmation HPLC can’t. Together — HPLC for purity, MS for identity — they’re the standard analytical pair for peptide characterization. Most research-grade CoAs include both.

The MS measurement reports the observed molecular mass of the compound, typically the singly-protonated molecular ion [M+H]⁺ or a multiply-charged variant. The observed mass gets compared to the theoretical mass calculated from the peptide sequence using standard monoisotopic atomic masses. A match within a few parts per million is strong evidence that the compound has the expected molecular composition.

Tandem mass spectrometry adds sequence-level confirmation by fragmenting the peptide along the backbone and comparing the fragment pattern to the expected fragmentation of the labeled sequence.

For most research-grade work, our baseline is a CoA with an HPLC trace at the ≥98% spec level and a mass spectrum confirming the expected molecular ion. Higher-stakes applications may need additional orthogonal characterization: peptide mapping by enzymatic digestion plus MS, amino acid analysis after acid hydrolysis, or full sequencing by Edman degradation or de novo MS sequencing.

Questions to bring to a supplier

If you’re evaluating an HPLC purity spec on a research-peptide CoA, these are the analytical questions worth asking:

• Does the CoA include the actual HPLC chromatogram, or only a summary statement? The trace is more independently verifiable than a summary number.
• At what wavelength, and on what column chemistry? Standard is 214 nm on C18. Deviations should be documented.
• What method conditions? Gradient, flow rate, column temperature, run time. Documented conditions support method reproducibility.
• Is the main peak identity confirmed by mass spectrometry? HPLC alone is purity. Identity needs MS or equivalent.
• What’s the resolution between the main peak and nearest impurity? Baseline resolution supports accurate integration. Poor resolution confounds purity calculation.
• Is the analytical method validated under ISO 17025 or equivalent? Method validation provides documented evidence of capability.